Your browser doesn't support javascript.
Effect of Ozone therapy in treatment of COVID-19
IRCT; 2020-04-18; TrialID: IRCT20191125045492N2
Clinical Trial Register | ICTRP | ID: ictrp-IRCT20191125045492N2
ABSTRACT

Condition

COVID-19.
COVID-19, virus not identified;U07.2

Intervention

Intervention 1 Intervention group In addition to the conventional treatments for Covid-19, patients will undergo a cycle of Ozone Major Autohemotherapy. In this method, a specific volume of patient's blood is drawn (100 to 200 cc in mild to moderate cases and 200 cc in severe cases). Then, a corresponding volume (100 to 200cc) of the oxygen-ozone gas mixture is added to the blood (initially with an ozone concentration of 35 micrograms/ml and gradually increasing it up to 45micrograms/ml in mild to moderate cases and up to 50micrograms/ml in severe cases). After mixing the blood with the gas mixture for at least 5 minutes with gentle rotating movements, the blood is reinfused to the patient. Mild to moderate cases will be treated daily for 4 days. Severe cases will be treated twice daily for at least 7 days. Intervention 2 Control group Patients of this group, will just get the conventional treatments for COVID-19.

Primary 

outcome:

Quantitative CRP. Timepoint Before and after the intervention. Method of measurement Lab kit.;Oxygen Saturation. Timepoint Before and after the intervention. Method of measurement Pulse Oximetry.;Body's temperature. Timepoint Before and after the intervention. Method of measurement Thermometer.;Dyspnea. Timepoint Before and after the intervention. Method of measurement Subjective assessment of the patient and physical examination.;Cough. Timepoint Before and after the intervention. Method of measurement subjective assessment of the patient.;Diarrhea. Timepoint before and after the intervention. Method of measurement subjective assessment of the patient.;Headache. Timepoint Before and after the intervention. Method of measurement Subjective assessment of the patient.;Chills. Timepoint Before and after the intervention. Method of measurement Subjective assessment of the patient.

Criteria

Inclusion criteria Patients who have been diagnosed with COVID-19

Exclusion criteria Patients with hypersensitivity to ozone
Patients with abnormal thyroid function tests
Patients with abnormal coagulation tests
Patients with G6PD deficiency
Pregnant or lactating women
Collection: Clinical trial registers Database: ICTRP Document Type: Clinical Trial Register Type of study: Controlled clinical trial Year: 2020

Similar

MEDLINE

...
LILACS

LIS

Collection: Clinical trial registers Database: ICTRP Document Type: Clinical Trial Register Type of study: Controlled clinical trial Year: 2020
...